← ANALYST RATINGS · TIPRANKS
Urogen Pharma (URGN): analyst forecast and price target
Analyst consensus
Strong Buy4 Buy1 Hold0 Sell
Ratings of 5 analysts in the last 3 months · top analysts only12-month forecast
Based on 5 price targets given in the last 3 months, the average target is $60.20, the highest $75.00, the lowest $48.00. The average is +74.2% from the last price of $34.56.
Analyst ratings 8
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $43.00 → $38.00−11.6% | Hold | +10.0% | Reiterated | 09.10.26on TipRanks 07:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $43.00 → $36.00−16.3% | Hold | +4.2% | Reiterated | 09.10.26on TipRanks 07:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $42.00 → $37.00−11.9% | Hold | +7.1% | Reiterated | 09.10.26on TipRanks 07:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $43.00 → $36.00−16.3% | Hold | +4.2% | Reiterated | 09.10.26on TipRanks 07:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $46.00 → $39.00−15.2% | Hold | +12.8% | Downgrade | 09.10.26on TipRanks 07:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $43.00 → $37.00−14.0% | Hold | +7.1% | Reiterated | 09.10.26on TipRanks 07:05 | — | |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $44.00 → $43.00−2.3% | Hold | +24.4% | Reiterated | 08.10.26on TipRanks 04:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $44.00 → $43.00−2.3% | Hold | +24.4% | Reiterated | 08.10.26on TipRanks 04:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $44.00 → $43.00−2.3% | Hold | +24.4% | Reiterated | 08.10.26on TipRanks 04:05 | — | |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $43.00 → $44.00+2.3% | Hold | +27.3% | Reiterated | 03.10.26on TipRanks 03:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $43.00 → $44.00+2.3% | Hold | +27.3% | Reiterated | 03.10.26on TipRanks 03:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $43.00 → $44.00+2.3% | Hold | +27.3% | Reiterated | 03.10.26on TipRanks 03:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $45.00 → $46.00+2.2% | Buy | +33.1% | Upgrade | 03.10.26on TipRanks 03:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $42.00 → $43.00+2.4% | Hold | +24.4% | Reiterated | 03.10.26on TipRanks 03:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $41.00 → $42.00+2.4% | Hold | +21.5% | Reiterated | 02.10.26on TipRanks 01:05 | — | |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $44.00 → $43.00−2.3% | Hold | +24.4% | Reiterated | 01.10.26on TipRanks 00:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $42.00 → $41.00−2.4% | Hold | +18.6% | Reiterated | 01.10.26on TipRanks 00:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $46.00 → $45.00−2.2% | Buy | +30.2% | Upgrade | 01.10.26on TipRanks 00:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $43.00 → $42.00−2.3% | Hold | +21.5% | Reiterated | 01.10.26on TipRanks 00:05 | — | |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $44.00 | Hold | +27.3% | Reiterated | 30.09.26on TipRanks 00:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $44.00 → $43.00−2.3% | Hold | +24.4% | Reiterated | 30.09.26on TipRanks 00:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $42.00 | Hold | +21.5% | Reiterated | 30.09.26on TipRanks 00:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $44.00 → $43.00−2.3% | Hold | +24.4% | Reiterated | 30.09.26on TipRanks 00:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $46.00 | Buy | +33.1% | Upgrade | 30.09.26on TipRanks 00:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $43.00 | Hold | +24.4% | Reiterated | 30.09.26on TipRanks 00:05 | — | |
| Ram Selvaraju★★★★★★★★★★#212 · hits 57% · avg +24.4% | H.C. Wainwright | $75.00 | Buy | +117.0% | Reiterated | 21.08.26on TipRanks Aug 20 06:25 | −6.1%next day −0.3% · 5 days −3.9% | ↗ |
| Leland Gershell★★★★★★★★★★#2332 · hits 40% · avg +6.2% | Oppenheimer | $50.00 → $60.00+20.0% | Buy | +73.6% | Reiterated | 06.08.26on TipRanks 08:30 | −1.6%next day +2.4% · 5 days +4.3% | ↗ |
| Paul Choi★★★★★★★★★★#1415 · hits 56% · avg +9.6% | Goldman Sachs | $44.00 → $48.00+9.1% | Hold | +38.9% | Reiterated | 05.08.26on TipRanks Aug 6 08:11 | +16.5%next day −1.6% · 5 days +5.2% | ↗ |
| Michael Schmidt★★★★★★★★★★#126 · hits 58% · avg +31.7% | Guggenheim | $42.00 → $58.00+38.1% | Buy | +67.8% | Reiterated | 05.08.26on TipRanks Aug 6 06:55 | +16.5%next day −1.6% · 5 days +5.2% | ↗ |
| Tara Bancroft★★★★★★★★★★#361 · hits 55% · avg +30.3% | TD Cowen | $50.00 → $60.00+20.0% | Buy | +73.6% | Assigned | 05.08.26on TipRanks 12:50 | +16.5%next day −1.6% · 5 days +5.2% | ↗ |
| Kevin DeGeeter★★★★★★★★★★#705 · hits 38% · avg +19.0% | Ladenburg Thalmann & Co. | $43.00 | Buy | +24.4% | Initiated | 11.05.26on TipRanks 08:35 | +6.3%next day −4.7% · 5 days −8.7% | ↗ |
| Kelsey Goodwin★★★★★★★★★★#203 · hits 68% · avg +62.4% | Piper Sandler | $40.00 | Buy | +15.7% | Reiterated | 20.04.26on TipRanks 07:07 | +10.8%next day +1.1% · 5 days −5.5% | ↗ |
| Amin Makarem★★★★★★★★★★#7369 · hits 50% · avg +43.4% | Jefferies | $40.00 | Buy | +15.7% | Initiated | 09.04.26on TipRanks Apr 14 00:06 | +6.9%next day +5.1% · 5 days +1.0% | ↗ |
| No ratings for this filter. | ||||||||
Every rating the collector has kept for the last 12 months, including the earlier ones of the same analyst. Latest of each analyst
Best analysts covering Urogen Pharma
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $60.20 at a price of $40.63 (+48.2%); now: $60.20 at $34.56 (+74.2%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 6 | 4 | 4 | 3 | 3 |
| Buy | 6 | 8 | 13 | 10 | 8 | 3 |
| Hold | 1 | 1 | 2 | 2 | 2 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 05.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $0.10 (from $-0.07 to $0.19). Last quarter: $-0.28.
Sales
Next quarter’s sales estimate — $91M (from $84M to $96M). Last quarter: $72M.
Best top-analyst consensus in the sector · Healthcare
About Urogen Pharma
- CEO: Elizabeth Barrett
- Employees: 300
- 400 Alexander Park Drive, Princeton, NJ, 08540, US
- www.urogen.com
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment of non-muscle invasive bladder cancer (NMIBC); and Jelmyto for pyelocalyceal solutions. The company’s lead product candidates are UGN-103, which is in phase 3 of clinical trial for intravesical solution; and UGN-104 that is in phase 3 of clinical trial for pyelocalyceal solution designed for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk NMIBC. It is also developing UGN-301, UGN-301+UGN 201, and UGN-301+gemcitabine that are in phase 1 of clinical trial for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 and UGN-104. UroGen Pharma Ltd. was incorporated in 2004 and is headquartered in Princeton, New Jersey.
Data from the stock’s TipRanks forecast page, read 128 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗